Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$485.99 USD
+4.10 (0.85%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $486.28 +0.29 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
VRTX 485.99 +4.10(0.85%)
Will VRTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) Rises 16.5% YTD: Time to Bet On the Stock?
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
Other News for VRTX
IN BRIEF: Vertex US application for cystic fibrosis treatment accepted
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Vertex to Announce Second Quarter 2024 Financial Results on August 1
Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board
Dynatrace initiated, U.S. Bancorp downgraded: Wall Street's top analyst calls